Dapagliflozin showed the largest reduction in composite renal outcomes, canagliflozin produced the most pronounced reduction in albuminuria, and both dulaglutide 1.5 mg and semaglutide demonstrated significant renal benefits, whereas exenatide showed only a nonsignificant trend.
← all excerpts
Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
1
—
—